Various Eateries (VE) continues to deliver on its Q320 IPO aspirations with ‘extremely strong’ trading since reopening in April and confirmation of prime site expansion on advantageous terms. In particular, its main brand Coppa Club grew like-for-like sales by 28% on 2019 in its first five weeks of indoor and outdoor dining from 17 May (UK restaurant market like-for-like sales up 8% in June, per Coffer CGA Business Tracker). Similarly, in the half to March 2021, business was encouraging when allowed to trade, ie October saw 10% higher like-for-like sales at Coppa Clubs outside London. A current opening in Clifton with Putney to follow exemplifies VE’s active growth strategy, facilitated by healthy liquidity (net cash at June 2021).
Various Eateries |
Raring to go!
|
Travel & leisure |
QuickView
22 July 2021 |
Share price graph
Share details
Business description
Bull
Bear
Analysts
|
||||||||||||||||||||||||
Various Eateries (VE) continues to deliver on its Q320 IPO aspirations with ‘extremely strong’ trading since reopening in April and confirmation of prime site expansion on advantageous terms. In particular, its main brand Coppa Club grew like-for-like sales by 28% on 2019 in its first five weeks of indoor and outdoor dining from 17 May (UK restaurant market like-for-like sales up 8% in June, per Coffer CGA Business Tracker). Similarly, in the half to March 2021, business was encouraging when allowed to trade, ie October saw 10% higher like-for-like sales at Coppa Clubs outside London. A current opening in Clifton with Putney to follow exemplifies VE’s active growth strategy, facilitated by healthy liquidity (net cash at June 2021).
Confidence undimmed
The pandemic has reinforced management’s conviction that its Coppa Club product, an all-day, multi-use venue with a clubhouse feel, increasingly addresses changes in consumer behaviour, accelerated by COVID-19. More flexible, remote working and the growing appeal of neighbourhood hospitality chime with Coppa Club’s wide proposition, ie restaurant, lounge, bar and workspace with outdoor seating, supplemented at two sites by accommodation and events and meeting spaces. The focus is on prime residential areas outside London notwithstanding an established major outlet at Tower Bridge. With over 50 Coppa Clubs (now eight) envisaged nationwide, management confirms a ‘very healthy’ pipeline with an autumn opening and several sites under negotiation. VE also sees scope for 100+ Tavolino, a neighbourhood Italian restaurant at mid-market prices (now just at Tower Bridge), initially with the conversion of two prominent company-owned Strada in London. A run rate of c 10 openings a year across the estate is planned.
H121 resilience
Despite the challenge of COVID-19 (20 weeks of closures and 7 weeks of curbs, hence 70% lower sales), the half to March 2021 saw maintained EBITDA break-even, bolstered by the receipt of a £2.5m business interruption insurance interim payment. £19m gross cash at the period end compared with c £24m at the start.
Valuation: Attractive
With no consensus forecasts and FY21 disrupted by COVID-19, we base valuation on management’s pro forma EBITDA based on 2019 performance, adjusted for later acquisitions. Its £5.3m pre-IFRS 16 EBITDA on June 2021 net cash of £8m suggests EV/EBITDA of 14x. This may prove undemanding if VE’s highly scalable model can capitalise on ’the most favourable market opportunities in a generation’.
|
Consensus estimates
Source: Refinitiv. Note: *Not meaningful, given transformative increase in issued share capital in connection with admission to AIM at very end of FY20. |
EDISON QUICKVIEWS ARE NORMALLY ONE-OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.
|
||||||||||||
|
||||||||||||
Research: Healthcare
AdAlta has announced it will be moving forward with an inhaled formulation of AD-214 into efficacy studies in patients with idiopathic pulmonary fibrosis (IPF) rather than the original intravenous (IV) formulation. Preclinical studies with a radiolabelled version of AD-214 have indicated that IV dosing leads to much of the administered drug being rapidly distributed through the liver and cleared, rendering it unavailable to deliver a therapeutic effect. The company believes the advantages of an inhaled formulation will include a more direct form of administrations for lung diseases, potentially lower drug doses required for efficacy, and lower costs to manufacture and administer.